The partners will use 4D Path's imaging-based Q-Plasia OncoReader in a Phase II trial testing doublet and triplet regimens comprising Trodelvy, Padcev, and Keytruda.
In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...
YouTube on MSN
Update from biopsy - Tom has prostate cancer
We received back the results of Tom's Prostate Biopsy and they did identify cancer in 3/15 core samples taken. The doctors ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment.
The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a ...
Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients ...
Amendment reduces and simplifies royalty structure on Teverelix ® from ~4% to 2% while preserving global rights and IP control The Company is ...
Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...
A novel long-term prediction model showed promise at estimating the risk for dying of prostate cancer, an analysis published in Annals of Internal Medicine indicated.“We have developed a tool that can ...
Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...
SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results